EPHA2 and neoplasm: The reasons for this difference are not known, but could be related to a number of factors including; a difference in the location of the 64Cu labeling, differences in serum stability, binding to an alternative epitope on EphA2, or the observation that B6 bound and accumulated to higher extent in the liver, thereby, sequestering B6 and preventing it from recirculating to the tumor site.